Your Health, We Care
Axitinib is a tyrosine kinase inhibitor primarily used for the treatment of renal cell carcinoma (RCC). It is an oral drug that acts on multiple targets such as the vascular endothelial growth factor receptor (VEGFR) to inhibit the growth of tumor cells by blocking tumor angiogenesis and metastasis pathways.
Axitinib was first approved by the FDA in January 2012 and approved by the CFDA in April 2015.
